Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  Zhao, Min ^a,b,c   Mantel, Irmela ^d   Gelize, Emmanuelle ^a,b,c   Li, Xinxin ^a,b,c   Xie, Xiaoyue ^a,b,c   Arboleda, Alejandro ^a,b,c,e   Seminel, Marie ^a,b,c   Levy Boukris, Rinath ^a,b,c   Dernigoghossian, Marilyn ^a,b,c   Prunotto, Andrea ^d   Andrieu Soler, Charlotte ^f   Rivolta, Carlo ^d,g   Canonica, Jérémie ^d   Naud, Marie Christine ^a,b,c   Lechner, Sebastian ^a,b,c   Farman, Nicolette ^a,b,c   Bravo Osuna, Irene ^h,i   Herrero Vanrell, Rocio ^h,i   Jaisser, Frederic ^a,b,c   Behar Cohen, Francine ^a,b,c,j  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HÔTEL DIEU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; MINERALOCORTICOID RECEPTOR; RANIBIZUMAB; SPIRONOLACTONE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; MICROSPHERE; MINERALOCORTICOID ANTAGONIST; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

A SCAN; AGE RELATED MACULAR DEGENERATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; LASER-INDUCED CHOROIDAL NEOVASCULARIZATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPTICAL COHERENCE TOMOGRAPHY; RETINA FLUORESCEIN ANGIOGRAPHY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC THERAPY; UPREGULATION; VISUAL IMPAIRMENT; WET MACULAR DEGENERATION; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CHOROID; DRUG EFFECT; DRUG FORMULATION; FEMALE; GENE EXPRESSION; GENETICS; LONG EVANS RAT; MACULAR DEGENERATION; MALE; METABOLISM; PATHOLOGY; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; TRANSGENIC MOUSE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DRUG COMPOUNDING; FEMALE; GENE EXPRESSION; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MICE; MICE, TRANSGENIC; MICROSPHERES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PILOT PROJECTS; PROSPECTIVE STUDIES; RANIBIZUMAB; RATS, LONG-EVANS; RECEPTORS, MINERALOCORTICOID; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SPIRONOLACTONE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85060254615     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-08125-6     Document Type: Article

References (67)

1. Wong, W. L.et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2, e106–e116 (2014)
2. Mitchell, P., Liew, G., Gopinath, B. & Wong, T. Y. Age-related macular degeneration. Lancet 392, 1147–1159 (2018)
3. Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325–330 (2011)
4. Celkova, L. & Doyle, S. L. & Campbell, M. NLRP3 inflammasome and pathobiology in AMD. J. Clin. Med. 4, 172–192 (2015)
5. Whitmore, S. S. et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog. Retin. Eye Res. 45, 1–29 (2015)
6. Witmer, A. N., Vrensen, G. F. J. M., Van Noorden, C. J. F. & Schlingemann, R. O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22, 1–29 (2003)
7. Bhutto, I. & Lutty, G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol. Asp. Med. 33, 295–317 (2012)
8. Campochiaro, P. A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 49, 67–81 (2015)
9. Zhang, S. X. & Ma, J. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin. Eye Res. 26, 1–37 (2007)
10. Ba, J. et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des. Devel. Ther. 9, 5397–5405 (2015)
11. Rezar-Dreindl, S. et al. The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 57, 4144–4150 (2016)
12. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials. Ophthalmology 123, 1751–1761 (2016)
13. Rush, R. B., Rush, S. W., Aragon, A. V. & Ysasaga, J. E. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Am. J. Ophthalmol. 158, 337–344 (2014)
14. Framme, C., Panagakis, G. & Birngruber, R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 51, 1671–1676 (2010)
15. Yang, S., Zhao, J. & Sun, X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel. Ther. 10, 1857–1867 (2016)
16. Miller, J. W. Beyond VEGF-the weisenfeld lecture. Invest. Ophthalmol. Vis. Sci. 57, 6911–6918 (2016)
17. Arnold, J. J., Markey, C. M., Kurstjens, N. P. & Guymer, R. H. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration–a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 16, 31 (2016)
18. CATT Research Group,.et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897–1908 (2011)
19. Gewaily, D., Muthuswamy, K. & Greenberg, P. B. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst. Rev. CD007324 (2015). 10.1002/14651858.CD007324.pub3
20. Cao, J. H., Mulvahill, M., Zhang, L., Joondeph, B. C. & Dacey, M. S. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology 121, 1871–1876 (2014)
21. Whitcup, S. M., Cidlowski, J. A., Csaky, K. G. & Ambati, J. Pharmacology of corticosteroids for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 59, 1–12 (2018)
22. Zhao, M. et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. Faseb J. 24, 3405–3415 (2010)
23. Zhao, M. et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 122, 2672–2679 (2012)
24. Daruich, A. et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 48, 82–118 (2015)
25. Daruich, A. et al. Oral mineralocorticoid-receptor antagonists: Real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol. 5, 2 (2016)
26. Bousquet, E. et al. Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study. Retina 35, 2505–2515 (2015)
27. Jaisser, F. & Farman, N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68, 49–75 (2016)
28. Crum, R., Szabo, S. & Folkman, J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230, 1375–1378 (1985)
29. Fujii, M. et al. Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J. Steroid Biochem. Mol. Biol. 129, 145–152 (2012)
30. Michel, F. et al. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation 109, 1933–1937 (2004)
31. Miternique-Grosse, A. et al. Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. J. Hypertens. 24, 2207–2213 (2006)
32. Wilkinson-Berka, J. L., Tan, G., Jaworski, K. & Miller, A. G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 104, 124–133 (2009)
33. Grossniklaus, H. E., Kang, S. J. & Berglin, L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 29, 500–519 (2010)
34. Kolkhof, P. & Bärfacker, L. 30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 234, T125–T140 (2017)
35. Zhao, M. et al. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J. Control. Release 266, 187–197 (2017)
36. Schäfer, N. et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur. Heart J. 34, 3515–3524 (2013)
37. Miller, J. W., Le Couter, J., Strauss, E. C. & Ferrara, N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120, 106–114 (2013)
38. Olsen, T. W., Feng, X., Kasper, T. J., Rath, P. P. & Steuer, E. R. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 111, 250–255 (2004)
39. Jung, J. J. et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am. J. Ophthalmol. 158, 769–779.e2 (2014)
40. Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537–2548 (2012)
41. Hussain, R. M. & Ciulla, T. A. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Exp. Opin. Emerg. Drugs 22, 235–246 (2017)
42. Kapoor, K. G., Todi, N. & Wagner, A. L. Mineralocorticoid antagonists as adjuncts in neovascular age-related macular degeneration. Ophthalmol. Ther. 6, 141–146 (2017)
43. Grunin, M., Hagbi-Levi, S. & Chowers, I. The role of monocytes and macrophages in age-related macular degeneration. Adv. Exp. Med. Biol. 801, 199–205 (2014)
44. Combadière, C. et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117, 2920–2928 (2007)
45. Usher, M. G. et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 120, 3350–3364 (2010)
46. Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344–1355 (2018)
47. Järveläinen, H., Sainio, A. & Wight, T. N. Pivotal role for decorin in angiogenesis. Matrix Biol. 43, 15–26 (2015)
48. Frikeche, J., Maiti, G. & Chakravarti, S. Small leucine-rich repeat proteoglycans in corneal inflammation and wound healing. Exp. Eye Res. 151, 142–149 (2016)
49. Keenan, T. D. L. et al. Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera. Invest. Ophthalmol. Vis. Sci. 53, 7528–7538 (2012)
50. Gubbiotti, M. A., Vallet, S. D., Ricard-Blum, S. & Iozzo, R. V. Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 55, 7–21 (2016)
51. Nelimarkka, L. et al. Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am. J. Pathol. 158, 345–353 (2001)
52. Schönherr, E. et al. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J. Vasc. Res. 41, 499–508 (2004)
53. Neill, T., Schaefer, L. & Iozzo, R. V. Decorin as a multivalent therapeutic agent against cancer. Adv. Drug Deliv. Rev. 97, 174–185 (2016)
54. Neill, T. et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 287, 5492–5506 (2012)
55. Du, S., Wang, S., Wu, Q., Hu, J. & Li, T. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells. Exp. Eye Res. 116, 151–160 (2013)
56. Xaus, J., Comalada, M., Cardó, M., Valledor, A. F. & Celada, A. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98, 2124–2133 (2001)
57. Mohan, R. R. et al. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS ONE 6, e26432 (2011)
58. Wang, X. et al. TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration. Sci. Rep. 7, 9672 (2017)
59. Yuan, X. et al. Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell. Proteom. 9, 1031–1046 (2010)
60. Gergely, R. et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: A comparative study of exudative and nonexudative fellow eyes. Retina 37, 1084–1091 (2017)
61. Funder, J. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history. J. Endocrinol. 234, T17–T21 (2017)
62. Barrera-Chimal, J. et al. Benefit of mineralocorticoid receptor antagonism in AKI: Role of vascular smooth muscle Rac1. J. Am. Soc. Nephrol. 28, 1216–1226 (2017)
63. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Förster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic. Res. 8, 265–277 (1999)
64. Mueller, K. B. et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 66, 988–997 (2015)
65. Fraccarollo, D. et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400–408 (2011)
66. Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483–486 (2010)
67. Wendling, O., Bornert, J. -M., Chambon, P. & Metzger, D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 47, 14–18 (2009)